

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/90076 A1

(51) International Patent Classification⁷: **C07D 213/89**, A61K 31/44, A61P 11/06

(74) Agents: **MITCHELL, Robert et al.**; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number: **PCT/CA01/00732**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 23 May 2001 (23.05.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/207,023 25 May 2000 (25.05.2000) US

(71) Applicant (*for all designated States except US*):
MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **FRIESEN, Richard** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **DUCHARME, Yves** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **GIRARD, Yves** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **LI, Chun** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **ROBICHAUD, Annette** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FLUOROALKOXY-SUBSTITUTED BENZAMIDE DICHLOROPYRIDINYL N-OXIDE PDE4 INHIBITOR



(57) Abstract: A PDE4 inhibiting compound is represented by formula (I).

WO 01/90076 A1

TITLE

5 FLUOROALKOXY-SUBSTITUTED BENZAMIDE
DICHLOROPYRIDINYL N-OXIDE PDE4 INHIBITOR

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

10 The present invention is directed to a fluoroalkoxy-substituted benzamide dichloropyridinyl *N*-oxide compound that is a phosphodiesterase-4 inhibitor. In particular, this invention is directed to *N*-(3,5-Dichloro-1-oxido-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide which is a phosphodiesterase-4 inhibitor.

15 RELATED BACKGROUND

Hormones are compounds that variously affect cellular activity. In many respects, hormones act as messengers to trigger specific cellular responses and activities. Many effects produced by hormones, however, are not caused by the singular effect of just the hormone. Instead, the hormone first binds to a receptor, thereby triggering the release of a second compound that goes on to affect the cellular activity. In this scenario, the hormone is known as the first messenger while the second compound is called the second messenger. Cyclic adenosine monophosphate (adenosine 3', 5'-cyclic monophosphate, "cAMP" or "cyclic AMP") is known as a second messenger for hormones including epinephrine, glucagon, calcitonin, corticotrophin, lipotropin, luteinizing hormone, norepinephrine, parathyroid hormone, thyroid-stimulating hormone, and vasopressin. Thus, cAMP mediates cellular responses to hormones. Cyclic AMP also mediates cellular responses to various neurotransmitters.

30 Phosphodiesterases ("PDE") are a family of enzymes that metabolize 3', 5' cyclic nucleotides to 5' nucleoside monophosphates, thereby terminating cAMP second messenger activity. A particular phosphodiesterase, phosphodiesterase-4 ("PDE4", also known as "PDE-IV"), which is a high affinity, cAMP specific, type IV PDE, has generated interest as potential targets for the development of novel anti-asthmatic and anti-inflammatory compounds. PDE4 is known to exist as at least four

isoenzymes, each of which is encoded by a distinct gene. Each of the four known PDE4 gene products is believed to play varying roles in allergic and/or inflammatory responses. Thus, it is believed that inhibition of PDE4, particularly the specific PDE4 isoforms that produce detrimental responses, can beneficially affect allergy and 5 inflammation symptoms. It would be desirable to provide novel compounds and compositions that inhibit PDE4 activity.

Inhibition of PDE4 activity is believed effective for the treatment of osteoporosis by reducing bone loss. For example, Ken-ichi Miyamoto et al., *Biochem. Pharmacology*, 54:613-617(1997) describes the effect of a PDE4 on bone loss. 10 Therefore, it would be desirable to provide novel compounds and compositions that inhibit PDE4 activity.

A major concern with the use of PDE4 inhibitors is the side effect of emesis which has been observed for several candidate compounds as described in C.Burnouf et al., ("Burnouf"), *Ann. Rep. In Med. Chem.*, 33:91-109(1998). B.Hughes 15 et al., *Br. J.Pharmacol.*, 118:1183-1191(1996); M.J.Perry et al., *Cell Biochem. Biophys.*, 29:113-132(1998); S.B.Christensen et al., *J.Med. Chem.*, 41:821-835(1998); and Burnouf describe the wide variation of the severity of the undesirable side effects exhibited by various compounds. As described in M.D.Houslay et al., *Adv. In Pharmacol.*, 44:225-342(1998) and D.Spina et al., *Adv. In Pharmacol.*, 44:33-20 89(1998), there is great interest and research of therapeutic PDE4 inhibitors.

Fluoroalkoxy-substituted Benzamide PDE4 inhibitors are described in U.S. Patent No./ 5,712,298 and International Publication No. WO 98/35683.

International Patent Publication WO94222852 describes quinolines as PDE4 inhibitors. A.H.Cook, et al., *J.Chem. Soc.*, 413-417(1943) describes gamma-pyridylquinolines. Other quinoline compounds are described in Kei Manabe et al., *J.Org. Chem.*, 58(24):6692-6700(1993); Kei Manabe et al., *J.Am. Chem. Soc.*, 115(12):5324-5325(1993); and Kei Manabe et al., *J.Am. Chem. Soc.*, 114(17):6940-25 6941(1992).

Compounds that include ringed systems are described by various 30 investigators as effective for a variety of therapies and utilities. For example, International Patent Publication No. WO 98/25883 describes ketobenzamides as calpain inhibitors, European Patent Publication No. EP 811610 and U.S. Patent Nos. 5,679,712, 5,693,672 and 5,747,541 describe substituted benzoylguanidine sodium channel blockers, U.S. Patent No. 5,736,297 describes ring systems useful as a 35 photosensitive composition.


U.S. Patent Nos. 5,491,147, 5,608,070, 5,622,977, 5,739,144, 5,776,958, 5,780,477, 5,786,354, 5,798,373, 5,849,770, 5,859,034, 5,866,593, 5,891,896, and International Patent Publication WO 95/35283 describe PDE4 inhibitors that are tri-substituted aryl or heteroaryl phenyl derivatives. U.S. Patent No. 5,580,888 describes PDE4 inhibitors that are styryl derivatives. U.S. Patent No. 5,550,137 describes PDE4 inhibitors that are phenylaminocarbonyl derivatives. U.S. Patent No. 5,340,827 describes PDE4 inhibitors that are phenylcarboxamide compounds. U.S. Patent No. 5,780,478 describes PDE4 inhibitors that are tetra-substituted phenyl derivatives. International Patent Publication WO 96/00215 describes substituted oxime derivatives useful as PDE4 inhibitors. U.S. Patent No. 5,633,257 describes PDE4 inhibitors that are cyclo(alkyl and alkenyl)phenyl-alkenyl (aryl and heteroaryl) compounds.

However, there remains a need for novel compounds and compositions that therapeutically inhibit PDE4 with minimal side effects.

15

SUMMARY OF THE INVENTION

A compound of this invention is represented by Formula (I):




(I).

20

A method of treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, orthosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid

arthritis, osteoporosis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration,
5 osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumor growth, or cancerous invasion of normal tissues comprises the step of administering a therapeutically effective amount of a compound represented by Formula (I):




10

(I).

DETAILED DESCRIPTION OF THE INVENTION


A compound of this invention is represented by Formula (I):

15



(I).

The compound of Formula (I) ("Compound I") is made from precursor compound II represented by Formula (II):



(II)

available from BYK Gulden Lomberg Chemische Fabrik GmbH, Konstanz, Germany. Compound II is itself a PDE4 inhibitor. However, Compound (I) has

- 5 pharmacokinetics that are very different from Compound (II). Further, the PDE4 inhibitory parameters and the brain barrier interaction of Compound (I) differ substantially from that of Compound (II). In particular, as shown below, the properties of Compound (I) with regard the brain barrier are unexpectedly superior to those properties demonstrated by Compound (II).

10

Compounds having PDE 4 inhibitory activity can be characterized using the following assay protocols.

Assays for Determining PDE 4 Inhibitory Activity

15

SPA based PDE activity assay protocol

Compounds which inhibit the hydrolysis of cAMP to AMP by the type-IV cAMP-specific phosphodiesterases were screened in 96-well plate format as follows:

20

In a 96 well-plate at 30°C was added the test PDE 4 inhibitory compound (dissolved in 2µl DMSO), 188µl of substrate buffer containing [2,8-³H]adenosine 3',5'-cyclic phosphate (cAMP, 100nM to 50µM), 10mM MgCl₂, 1mM EDTA, 50mM Tris, pH 7.5. The reaction was initiated by the addition of 10µl of human recombinant PDE-IV (the amount was controlled so that ~10% product was formed in 10min. at 30°C). The reaction was stopped after 10min. by the addition of 1mg of PDE-SPA beads (Amersham). The product AMP generated was quantified on a Microbeta 96-well plate counter. The signal in the absence of enzyme was defined as the background. 100% activity was defined as the signal detected in the presence of enzyme and DMSO with the background subtracted. Percentage of inhibition was

calculated accordingly. IC₅₀ value was approximated with a non-linear regression fit of the standard 4-parameter/multiple binding sites equation from a ten point titration.

LPS and fMLP-Induced TNF- α and LTB₄ Assays in Human Whole Blood

- 5 Whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as PDE4-selective inhibitors. Normal non-stimulated human blood does not contain detectable levels of TNF- α and LTB₄. Upon stimulation with LPS, activated monocytes express and secrete TNF- α up to 8 hours and plasma levels remain stable for 24 hours.
- 10 Published studies have shown that inhibition of TNF- α by increasing intracellular cAMP via PDE4 inhibition and/or enhanced adenylyl cyclase activity occurs at the transcriptional level. LTB₄ synthesis is also sensitive to levels of intracellular cAMP and can be completely inhibited by PDE4-selective inhibitors. As there is little LTB₄ produced during a 24 hour LPS stimulation of whole blood, an additional LPS
- 15 stimulation followed by fMLP challenge of human whole blood is necessary for LTB₄ synthesis by activated neutrophils. Thus, by using the same blood sample, it is possible to evaluate the potency of a compound on two surrogate markers of PDE4 activity in the whole blood by the following procedure.

- Fresh blood was collected in heparinized tubes by venipuncture from
- 20 healthy human volunteers (male and female). These subjects had no apparent inflammatory conditions and had not taken any NSAIDs for at least 4 days prior to blood collection. 500 μ L aliquots of blood were pre-incubated with either 2 μ L of vehicle (DMSO) or 2 μ L of test compound at varying concentrations for 15 minutes at 37°C. This was followed by the addition of either 10 μ L vehicle (PBS) as blanks or
- 25 10 μ L LPS (1 μ g/mL final concentration, #L-2630 (Sigma Chemical Co., St. Louis, MO) from *E. coli*, serotype 0111:B4; diluted in 0.1% w/v BSA (in PBS)). After 24 hours of incubation at 37°C, another 10 μ L of PBS (blank) or 10 μ L of LPS (1 μ g/mL final concentration) was added to blood and incubated for 30 minutes at 37°C. The blood was then challenged with either 10 μ L of PBS (blank) or 10 μ L of fMLP (1 μ M
- 30 final concentration, #F-3506 (Sigma); diluted in 1% w/v BSA (in PBS)) for 15 minutes at 37°C. The blood samples were centrifuged at 1500xg for 10 minutes at 4°C to obtain plasma. A 50 μ L aliquot of plasma was mixed with 200 μ L methanol for protein precipitation and centrifuged as above. The supernatant was assayed for LTB₄ using an enzyme immunoassay kit (#520111 from Cayman Chemical Co., Ann

Arbor, MI) according to the manufacturer's procedure. TNF- α was assayed in diluted plasma (in PBS) using an ELISA kit (Cistron Biotechnology, Pine Brook, NJ) according to manufacturer's procedure. The IC₅₀ values of Examples 1-42 generally ranged from 0.04 μ M to 8.71 μ M.

5

Effect on Duration of Anesthesia

Compound I of the present invention was compared to Compound II by testing the effects on the duration of anesthesia induced by the combination of xylazine and ketamine in rats. Male Sprague-Dawley rats were anaesthetised with a 10 combination of xylazine (10mg/kg) and ketamine (10mg/kg) administered in a single intramuscular injection in the back hindlimb. Fifteen minutes later, the drug to be tested or its vehicle was injected intraperitoneally (dosing volume = 1ml/kg) and the animals were placed in dorsal recumbence. The compounds were dissolved immediately before use in polyethylene glycol (M.W. 200). The return of the righting 15 reflex (i.e. when the animal no longer remained on its back and turned itself spontaneously to the prone position) was used as an endpoint to determine the duration of anaesthesia.

At the end of the experiment, at 60 minutes post-dosing, plasma and brain samples were taken for drug concentration determination. Referring to Table 1 20 below, administration of Compound I (3mg/kg i.p, n=5) did not significantly modify the duration of anaesthesia. By contrast, the administration of Compound II (3mg/kg i.p., n=5) led to a significant reduction in the duration of the anaesthesia induced by the combination of xylazine/ketamine.

Table 1

Effect of Compounds I and II on the duration of anesthesia induced by the combination of xylazine and ketamine in rats.

5

Results are expressed as mean \pm S.E.M.

Treatment (3mg/kg, i.p.)	Duration of anesthesia (min)		Inhibition %
	Vehicle treated group (n=8-9)	Compound treated group (n=5)	
Compound Formula I	44.33 \pm 4.81	37.40 \pm 7.83	15.6
Compound Formula II	42.38 \pm 4.98	19.20 \pm 4.68	54.7

Referring to Table 2 below, analysis of the plasma and brain samples revealed that both compounds were absorbed. However, the distribution to the brain 10 was very different for each compound. Consistent with the *in vivo* data on the duration of anaesthesia, Compound Formula I was found to be less brain permeable than compound of Formula II.

15


Table 2
Plasma and brain concentrations of Compounds I and II



Compound	Plasma (μ M)	Brain (μ M)	Brain/plasma %	n
Compound Formula I	4.37 \pm 1.65	0.41 \pm 0.15	9.38	5
Compound Formula II	0.20 \pm 0.08	0.15 \pm 0.05	75	5

Accordingly, while disadvantageously Compound II readily crosses the brain barrier, Compound (I) unexpected and advantageously does not readily cross the 20 brain barrier.

Compound (I) can be made according to the following procedure shown in Scheme I:

Scheme I





5


The synthesis of Compound (II) is described in U.S. Patent No. 5,712,298 and the compound is available from BYK Gulden (Konstanz, Germany). Compound I was obtained from Compound II by the following procedure:

10

EXAMPLE 1 - COMPOUND I

N-(3,5-Dichloro-1-oxido-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide

15



A mixture of *N*-(3,5-Dichloropyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide (3.0g, 7.4mmol) and magnesium

monoperoxyphthalate hexahydrate ("MMPP") (7.36g, 14.9mmol) in CH₂Cl₂/MeOH (100mL) was stirred under reflux for 48h. An additional amount of magnesium monoperoxyphthalate hexahydrate (7.4g, 15mmol) was added and the reaction mixture was stirred under reflux for an additional 24h. Ethyl acetate was then added
5 and the organic phase was washed by 25% aqueous NH₄OAc, water and brine, dried (MgSO₄) and concentrated. The residue was purified by column chromatography on silica (EtOAc) to yield N-(3,5-Dichloro-1-oxido-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide (Compound I) as a white solid (1.98 g, 63%). ¹H NMR (500MHz, acetone-d₆): δ 0.40 (m, 2H), 0.60 (m, 2H), 1.30 (m, 1H), 4.0 (d, 2H),
10 7.05 (t, 1H), 7.35 (d, 1H), 7.7 (m, 1H), 7.75 (s, 1H), 8.40 (s, 2H), 9.6 (bs, 1H).

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other
15 therapeutic ingredients or adjuvants. Such additional therapeutic ingredients include, for example, i) Leukotriene receptor antagonists, ii) Leukotriene biosynthesis inhibitors, and iii) M₂/M₃ antagonists. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in
20 any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

Creams, ointments, jellies, solutions, or suspensions containing the
25 compound of Formula I can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.

Dosage levels from about 0.01mg/kg to about 140mg/kg of body weight per day are useful in the treatment of conditions such as asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis
30 and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in

animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, 5 fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumor growth, or cancerous invasion of normal tissues which are responsive to PDE4 inhibition, or alternatively about 0.5mg to about 10 7g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01mg to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day. Further, it is understood that the PDE4 inhibiting compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited 15 conditions.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5mg to 20 about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1mg to about 500mg of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or 1000mg.

25 It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

In practice, the compound represented by Formula I, or 30 pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of 35 the present invention can be presented as discrete units suitable for oral administration

such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I. The compound of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or

adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of 5 the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.1mg to about 500mg of the active ingredient and each cachet or capsule preferably containing from about 0.1mg to about 500mg of the active ingredient.

10 Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

15 Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability.

20 The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

25 Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 30 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form 35 suitable for rectal administration wherein the carrier is a solid. It is preferable that the

mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.

5 In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation
10 isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

The compounds and pharmaceutical compositions of this invention have been found to exhibit biological activity as PDE4 inhibitors. Accordingly,
15 another aspect of the invention is the treatment in mammals of, for example, asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic
20 glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, orthosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, osteoporosis, ankylosing spondylitis,
25 transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumor growth, or cancerous invasion of normal
30 tissues – maladies that are amenable to amelioration through inhibition of the PDE4 isoenzyme and the resulting elevated cAMP levels – by the administration of an effective amount of the compounds of this invention. The term “mammals” includes humans, as well as other animals such as, for example, dogs, cats, horses, pigs, and cattle. Accordingly, it is understood that the treatment of mammals other than


humans is the treatment of clinical correlating afflictions to those above recited examples that are human afflictions.

Further, as described above, the compound of this invention can be utilized in combination with other therapeutic compounds. In particular, the
5 combinations of the PDE4 inhibiting compound of this invention can be advantageously used in combination with i) Leukotriene receptor antagonists, ii)
Leukotriene biosynthesis inhibitors, or iii) M2/M3 antagonists.

Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention
10 is not to be limited except as set forth in the following claims.

WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



5

(I).


2. A pharmaceutical composition comprising a therapeutically effective amount of
the compound according to claim 1 or a pharmaceutically acceptable
10 salt thereof; and
a pharmaceutically acceptable carrier.

3. The pharmaceutical composition according to claim 2, further comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, or
15 an M2/M3 antagonist.

4. A method of treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in
20 horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis,
25 arteriosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration,

osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumor growth, or cancerous invasion of normal tissues comprising the step of administering a therapeutically effective amount of the compound represented by Formula (I):

5



(I).

5. The compound of Formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof for use as a phosphodiesterase-4 inhibitor.

5 6. Use of the compound of Formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, 10 ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, 15 arteriosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated 20 chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumor growth, or cancerous invasion of normal tissues comprising the step of administering a therapeutically effective amount of the compound represented by Formula (I).

25 7. A PDE4 inhibitor pharmaceutical composition comprising an acceptable PDE4 inhibiting amount of a compound of Formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 01/00732A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D213/89 A61K31/44 A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 01338 A (BYK GULDEN LOMBERG CHEM FAB ;AMSCHLER HERMANN (DE)) 12 January 1995 (1995-01-12) claim 1; example 5 page 19 -page 22 page 12, paragraph 2 - paragraph 4 ---	1-7
Y	WO 98 35683 A (BYK GULDEN LOMBERG CHEM FAB ;EISTETTER KLAUS (DE); HAEFNER DIETRIC) 20 August 1998 (1998-08-20) cited in the application examples 1-5 ---	1,2,4-7
Y	WO 96 31476 A (RHONE POULENC RORER LTD ;COX PAUL JOSEPH (GB); NEWTON CHRISTOPHER) 10 October 1996 (1996-10-10) claims 1,35-39; example 1 ---	1,2,4-7 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

2 October 2001

Date of mailing of the international search report

17/10/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/00732

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 497 564 A (RHONE POULENC RORER LTD) 5 August 1992 (1992-08-05) page 5, line 42 - line 47 claims 1,11; example AV ----	1,2,4-7
Y	WO 94 02465 A (MORLEY ANDREW DAVID ;PALFREYMAN MALCOLM NORMAN (GB); RHONE POULENC) 3 February 1994 (1994-02-03) claims 1-5,20,27,30; examples AV,DR,DT,DY ----	1,2,4-7
P,X	WO 01 13953 A (BYK GULDEN LOMBERG CHEM FAB ;KILIAN ULRICH (DE)) 1 March 2001 (2001-03-01) claim 11 ----	1,2,4-7
P,X	WO 00 66123 A (BYK GULDEN LOMBERG CHEM FAB ;KILIAN ULRICH (DE)) 9 November 2000 (2000-11-09) claim 1 ----	1,2,4-7
P,X	D.S. BUNDSCUH: "In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4-Inhibitor" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 1, 2001, pages 280-290, XP001024809 the whole document ----	1,2,4-7
P,X	A. HATZELMANN: "Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4-Inhibitor Roflumilast in Vitro" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 1, 2001, pages 267-279, XP001024814 the whole document ----	1,2,4-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/00732

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9501338	A	12-01-1995		AU 687087 B2 AU 7490794 A CA 2165192 A1 CN 1126468 A ,B CZ 9600001 A3 WO 9501338 A1 EP 0706513 A1 FI 956333 A HU 73232 A2 JP 8512041 T JP 3093271 B2 NO 955211 A NZ 271316 A PL 311820 A1 RU 2137754 C1 SK 161795 A3 US 5712298 A		19-02-1998 24-01-1995 12-01-1995 10-07-1996 12-06-1996 12-01-1995 17-04-1996 29-12-1995 29-07-1996 17-12-1996 03-10-2000 21-12-1995 24-11-1997 18-03-1996 20-09-1999 03-07-1996 27-01-1998
WO 9835683	A	20-08-1998		DE 19705924 A1 AU 734122 B2 AU 6497398 A BR 9807399 A CN 1248169 T EE 9900279 A WO 9835683 A1 EP 0977577 A1 NO 993875 A PL 335134 A1 TR 9901772 T2 HU 0001043 A2		27-08-1998 07-06-2001 08-09-1998 14-03-2000 22-03-2000 15-02-2000 20-08-1998 09-02-2000 11-08-1999 10-04-2000 21-09-1999 28-09-2000
WO 9631476	A	10-10-1996		AU 5282796 A WO 9631476 A1		23-10-1996 10-10-1996
EP 0497564	A	05-08-1992		AT 132134 T AT 165334 T AU 664694 B2 AU 1188192 A AU 4565196 A CA 2101423 A1 CZ 9301528 A3 DE 69207017 D1 DE 69207017 T2 DE 69225245 D1 DK 497564 T3 EP 0497564 A1 EP 0569414 A1 EP 0669311 A1 ES 2081563 T3 FI 933357 A WO 9212961 A1 GR 3018544 T3 HU 64942 A2 HU 9500720 A3 IE 920247 A1 IL 100788 A JP 2664538 B2 JP 6504782 T		15-01-1996 15-05-1998 30-11-1995 27-08-1992 02-05-1996 29-07-1992 13-04-1994 08-02-1996 05-09-1996 28-05-1998 29-01-1996 05-08-1992 18-11-1993 30-08-1995 01-03-1996 19-08-1993 06-08-1992 31-03-1996 28-03-1994 28-12-1995 29-07-1992 10-01-1997 15-10-1997 02-06-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/00732

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0497564	A		MX 9200344 A1 NO 932701 A NZ 241427 A PL 169994 B1 SK 80993 A3 US 5935978 A US 6255326 B1 US 5698711 A ZA 9200547 A	01-03-1993 21-09-1993 26-08-1994 30-09-1996 08-12-1993 10-08-1999 03-07-2001 16-12-1997 03-05-1993
WO 9402465	A	03-02-1994	AU 4717693 A CA 2140441 A1 CZ 9500147 A3 EP 0652868 A1 FI 950375 A WO 9402465 A1 HU 72656 A2 HU 211979 B3 JP 8503925 T MX 9304571 A1 NO 950319 A NZ 254881 A PL 307265 A1 US 5935978 A US 5679696 A US 6255326 B1 US 5698711 A ZA 9305448 A US 5840724 A	14-02-1994 03-02-1994 17-07-1996 17-05-1995 27-01-1995 03-02-1994 28-05-1996 29-01-1996 30-04-1996 31-05-1994 27-03-1995 25-09-1996 15-05-1995 10-08-1999 21-10-1997 03-07-2001 16-12-1997 19-05-1994 24-11-1998
WO 0113953	A	01-03-2001	AU 6701600 A WO 0113953 A2	19-03-2001 01-03-2001
WO 0066123	A	09-11-2000	AU 4558800 A WO 0066123 A1	17-11-2000 09-11-2000